INTRODUCTION
Fixed drug eruption (FDE) is a cutaneous drug reaction which recurs at
the same site when the individual is exposed to the causative drug. The
eruption is characterized by single or multiple round sharply demarcated
erythematous-to-violaceous patches and rarely with generalized bullae
resembling Stevens-Johnson syndrome or toxic epidermal necrolysis. The
erythematous-to-violaceous hue usually improves over several days,
resulting in a characteristic round hyperpigmented patch [1].
Although the culprit agent is usually a medication, such as a sulfa
antibiotic or a nonsteroidal anti-inflammatory drug (NSAID), FDE has
also been reported following vaccinations such as the influenza, yellow
fever, and human papilloma virus vaccines [1-3].
To date, only five cases of FDE following COVID-19 vaccination have been
reported, 3 following mRNA and 2 after adenoviral vector-based vaccines
(Table 1 ) [4-8]. Here, we report a patient with generalized
non-bullous fixed drug eruption following vaccination with the
mRNA-based Pfizer-BioNTech COVID-19 vaccine.